v3.26.1
Segment Reporting
 9 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

NOTE 14 – Segment Reporting

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the CODM in deciding how to allocate resources in assessing performance. The Company has one reportable segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and stimulation solutions (“Neuromodulation Products”). NeuroOne is a medical technology company focused on developing and commercializing Neuromodulation Products. The Company recognizes the Neuromodulation Products as one reporting segment.

 

The accounting policies of the Neuromodulation Products segment are the same as those described in the summary of significant accounting policies. The CODM assesses performance for the Neuromodulation Products segment based on net loss, which is reported on the statements of operations as net loss. The measure of segment assets is reported on the balance sheet as total assets. The Company does not have any intra-entity sales or transfers.

 

The CODM uses cash forecast models in deciding how to invest into the Neuromodulation Products segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment and in establishing management’s compensation. 

  

The statements of operations below are inclusive of the significant expense categories regularly reviewed by the CODM for the three and nine months ended June 30, 2026 and 2025:

 

    Three months ended
June 30,		     Nine months ended
June 30,		  
    2026     2025     2026     2025  
Product revenue   $ 1,973,105     $ 1,696,050     $ 6,727,790     $ 6,356,767  
Cost of product revenue     790,496       781,215       2,987,089       2,743,982  
Product gross profit     1,182,609       914,835       3,740,701       3,612,785  
                                 
License revenue     —       —       —       3,000,000  
                                 
Operating expenses:                                
General and administrative     1,693,450       1,264,808       4,651,242       4,501,069  
Sales     261,079       150,009       634,372       512,361  
Marketing     227,239       204,133       700,980       589,388  
Development     1,172,517       1,039,733       3,727,222       3,379,700  
Quality assurance     252,636       142,752       555,701       485,676  
Total operating expenses     3,606,921       2,801,435       10,269,517       9,468,194  
Loss from operations     (2,424,312 )     (1,886,600 )     (6,528,816 )     (2,855,409 )
Fair value change in warrant liability     405,702       319,625       620,171       1,099,421  
Financing costs     —       (9,325 )     —       (334,063 )
Other income     12,279       75,432       82,402       103,898  
Loss before income taxes     (2,006,331 )     (1,500,868 )     (5,826,243 )     (1,986,153 )
Provision for income taxes     —       —       —       —  
Net loss   $ (2,006,331 )   $ (1,500,868 )   $ (5,826,243 )   $ (1,986,153 )